While mesothelioma is a problem in all states, the specific incident rate for Montana is 1.4 / 100,000. This is above the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in MT, recent MT mesothelioma-related court cases, mesothelioma specialists in MT and potential asbestos hotspots in Montana.
[doptabs]
[doptab title=”Overview”]
Montana Mesothelioma Info
By clicking on the above tabs, you will find information on mesothelioma specific to the state of Montana
Montana Research and Clinical Trials
This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.
Montana Doctors and Hospitals
This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.
Montana Cases
This is a partial list of relevant court cases on mesothelioma in your state.
Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.
[/doptab]
[doptab title=”Treatment and Research”]
Research
[dopaccordions]
[dopaccordion title=”Pershouse, Mark A. Mt Cobre: Effect Of Metal Mixtures On Gene Expression & Carcinogenesis
Grant: 5P20RR017670-058036″ icon=27 activeicon=28]
Abstract: This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Mesotheliomas are tumors that form in the mesothelial lining of the peritoneal, pleural or pericardial cavities. There is a strong tie to asbestos exposure, with tumors arising in 10% exposed workers and a history of asbestos exposure in about 70% to 80% of all patients with mesothelioma. Tumors form through poorly understood mechanisms involving a small number of genetic lesions, allowing escape from normal cellular growth control. Published reports strongly implicate a small set of tumor suppressor genes or oncogenes involved in regulating normal cellular growth: specifically the retinoblastoma (Rb) gene, the p53 gene, p16 and p14/ARF genes, and the neurofibromatosis 2 gene (NF2). NF2 and p16/p14ARF are consistently inactivated by mutations in the DNA, while p53 and RB suffer few mutations, but are inactivated by other mechanisms. In addition, a transforming DNA tumor virus, SV40, is thought to play a role in tumor formation. We hope to better understand the role of two of these genes in inactivating p53: SV40 Large T antigen (Tag), and NF2. Our hypothesis is that both genes effectively target the p53 gene for inactivation. Our study design involves creation of in vitro and in vivo models of tumor formation. These models involve either the induction of SV40 Tag expression in normal mouse lung via a viral delivery system or the study of asbestos-induced tumor formation in NF2 knockout mice. We will readout the results of these genetic changes by cellular transformation assays in in vitro models or tumor incidence in animal models.
Tags: There Are No Thesaurus Terms On File For This Project.
[/dopaccordion]
[/dopaccordions]
Clinical Trials
[dopaccordions]
[dopaccordion title=”Active, not recruiting Pazopanib in Treating Patients With Malignant Pleural Mesothelioma” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: pazopanib hydrochloride;
Other: laboratory biomarker analysis
More Information
[/dopaccordion]
[dopaccordion title=”Active, not recruiting AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: cediranib maleate
More Information
[/dopaccordion]
[dopaccordion title=”Suspended Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: everolimus
More Information
[/dopaccordion]
[dopaccordion title=”Completed Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: erlotinib hydrochloride
More Information
[/dopaccordion]
[dopaccordion title=”Active, not recruiting Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information
[/dopaccordion]
[/dopaccordions]
[/doptab]
[doptab title=”Doctors and Hospital”]
Hospital and Cancer Centers
We do not have any doctors or cancer centers for this state at the moment.
[/doptab]
[doptab title=”Cases”]
Cases
Orr v. State
No. 02-693 , SUPREME COURT OF MONTANA, June 26, 2003, Argued; November 12, 2003, Submitted , December 14, 2004, Decided
[/doptab]
[doptab title=”Lawyers”]
Lawyers
If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:
[/doptab]
[/doptabs]